Methadone and buprenorphine are the only two opioids that are indicated for the management of both pain and opioid-related drug addiction. Both present unique challenges to the general practitioner and pain specialist, requiring a separate analysis from the rest of the drugs in the same family. Handbook of Methadone Prescribing and Buprenorphine Therapy is an invaluable guide to the safe use of these opioids. Authored by clinical and academic leaders from a variety of settings and backgrounds, this book includes chapters on pharmacology, adverse effects, safe rotation from other opioids, cardiac toxicity, prescribing, pharmacokinetics, equianalgesic dose and replacement therapy. This comprehensive text provides clinicians, researchers, policy-makers and academicians a resource for all the relevant points in methadone prescribing and buprenorphine therapy.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat opioid use disorder (OUD)—methadone, naltrexone, and buprenorphine—and provides guidance for healthcare professionals and addiction treatment providers on appropriate prescribing practices for these medications and effective strategies for supporting the patients utilizing medication for the treatment of OUD. The goal of treatment for opioid addiction or OUD is remission of the disorder leading to lasting recovery. Recovery is a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential. This TIP also educates patients, families, and the general public about how OUD medications work and the benefits they offer. Related products: Medication-Assisted Treatment of Opioid Use Disorder: Pocket Guide A Shared Burden: The Military and Civilian Consequences of Army Pain Management Since 2001 Click our Alcoholism, Smoking & Substance Abuse collection to find more resources on this topic.

The Federal Guidelines for Opioid Treatment Programs (Guidelines) describe the Substance Abuse and Mental Health Services Administration's (SAMHSA) expectation of how the federal opioid treatment standards found in Title 42 of the Code of Federal Regulations Part 8 (42 CFR § 8) are to be satisfied by opioid treatment programs (OTPs). Under these federal regulations, OTPs are required to have current valid accreditation status, SAMHSA certification, and Drug Enforcement Administration (DEA) registration before they are able to administer or dispense opioid drugs for the treatment of opioid addiction.

"This book provides pharmacists with an overview of pharmacological therapies for opioid use disorders and information about related issues pertaining to pharmacy practice. Its main focus is to provide information on evidence-based treatment of opioid dependence using opioid agonists--methadone and buprenorphine--while acknowledging the importance of behavioural interventions such as psychosocial counselling."--

Learn best practices and evidence-based guidelines for assessing and managing pain! Assessment and Multimodal Management of Pain: An Integrative Approach describes how to provide effective management of pain through the use of multiple medications and techniques, including both pharmacologic and non-pharmacologic treatment regimens. A holistic approach provides an in-depth understanding of pain and includes practical assessment tools along with coverage of opioid and non-opioid analgesics, interventional and herbal approaches to pain, and much more. Written by experts Maureen F. Cooney and Ann Quinlan-Colwell, this reference is a complete, step-by-step guide to contemporary pain assessment and management. - Evidence-based, practical guidance helps students learn to plan and implement pain management, and aligns with current guidelines and best practices. - Comprehensive information on the pharmacologic management of pain includes nonopioid analgesics, opioid analgesics, and co-analgesics, including dose titration, routes of administration, and prevention of side effects. - UNIQUE! Multimodal approach for pain management is explored throughout the book, as it affects assessment, the physiologic experience, and the culturally determined expression, acknowledgement, and management of pain. - UNIQUE! Holistic, integrative approach includes thorough coverage of pain management with non-pharmacologic methods. - Clinical scenarios are cited to illustrate key points. - Equivalent analgesic action for common pain medications provides readers with useful guidance relating to medication selection. - Pain-rating scales in over 20 languages are included in the appendix for improved patient/clinician communication and accurate pain assessment. - UNIQUE! Authors Maureen F. Cooney and Ann Quinlan-Colwell are two of the foremost authorities in multimodal pain assessment and management. - Sample forms, guidelines, protocols, and other hands-on tools are included, and may be reproduced for use in the classroom or clinical setting.

Throughout the world, hundreds of thousands of people are addicted to opiates. The human, economic, and societal costs of this addiction are staggering: more than one-quarter of prison inmates are incarcerated for drug offenses and there has been a dramat.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

The second edition of the formerly titled Just Say Know: A Counsellor’s Guide to Psychoactive Drugs, this indispensable counselling resource provides a practical understanding of psychoactive drug pharmacology and physiology. Rick Csiernik unpacks the risks and therapeutic applications of the most commonly used and misused drug families, including depressants, stimulants, hallucinogens, and psychotherapeutics. This new edition features a wide range of updated research and content addressing the recent rise of opioid, fentanyl, cannabis, novel psychoactive substances, and antipsychotic medication use, as well as the impacts of drug use on sleep and mental health. Two new appendixes are featured summarizing the effects of drugs on pregnancy and interactions drugs may have with certain brain chemicals. The Essential Guide to Psychoactive Drugs in Canada is the perfect addition to any addiction or mental health-related course. User-friendly and highly readable, this resource serves as a guide for service providers to deliver evidence-based care. This text is crucial for counsellors, therapists, instructors, and students looking to acquire an in-depth practical understanding of drug use, medication, and addiction in disciplines such as social work, sociology, pharmacology, health studies, nursing, psychology, and addiction studies.

With a new foreword by Nora Volkow, Director of the National Institute on Drug Abuse, this second edition of Office-Based Buprenorphine Treatment of Opioid Use Disorder provides updated information on evidence-based treatment for opioid use disorder (OUD) -- an increasingly important topic as the epidemic of opioid misuse and overdose deaths grows in the United States. Bulleted clinical pearls at the end of each chapter, as well as specific clinical recommendations and detailed case discussions throughout, make it easier for readers to retain knowledge and integrate it into their clinical practice. The guide also features sample documentation and scales, including a treatment contract and a patient consent, that can be used to model documents in practice. This new edition of Office-Based Buprenorphine Treatment has been updated to reflect DSM-5 language, and two additional chapters have been included: one that addresses other pharmacotherapies useful in treating OUD, including methadone and naltrexone, and another that discusses OUD treatment specifically with regard to women's health and pregnancy. Among the numerous other revisions included in the second edition are the following: Information about new formulations of buprenorphine A discussion of the Comprehensive Addiction and Recovery Act (CARA) Changes to induction and maintenance target doses and recommendations for home inductions Information on diversion control plans Advice for working with Alcoholics Anonymous and Narcotics Anonymous A discussion on integrating buprenorphine into residential and inpatient opioid treatment programs This edition can also be used to complete the 8 hours of qualifying training required for the buprenorphine waiver. By a thorough reading of the material covered in the chapters of this book and successful completion of the posttest, physicians can meet the buprenorphine waiver training requirement. Written in a jargon-free style that does not require expertise in substance use disorder treatment, Office-Based Buprenorphine Treatment of Opioid Use Disorder is an accessible, indispensable reference for primary care physicians, psychiatrists, nurse practitioners, residents, medical students, and anyone with an interest in learning about and prescribing buprenorphine.